ST Human Welfare announced that in order to implement the “nuclear focus”, the wholly-owned subsidiary RFSW Holding Pte. Ltd. publicly listed and transferred 81.7 million shares of Lefus. On July 28, 2026, a “property rights transaction contract” was signed with Wuhan Hairun Biology Co., Ltd., with a transaction price of 1,062 billion yuan, an increase of 635 million yuan over book value, with a value-added rate of 148.42%. The funds will be used for production and operation, which is expected to affect current profit and loss of about 500 million yuan. The transaction has already been reviewed by the board of directors, and there is no need for shareholders' review. Subsequent matters will be handled in accordance with the Beijing Stock Exchange rules. There is uncertainty during the transition period.

ST Human Welfare announced that in order to implement the “nuclear focus”, the wholly-owned subsidiary RFSW Holding Pte. Ltd. publicly listed and transferred 81.7 million shares of Lefus. On July 28, 2026, a “property rights transaction contract” was signed with Wuhan Hairun Biology Co., Ltd., with a transaction price of 1,062 billion yuan, an increase of 635 million yuan over book value, with a value-added rate of 148.42%. The funds will be used for production and operation, which is expected to affect current profit and loss of about 500 million yuan. The transaction has already been reviewed by the board of directors, and there is no need for shareholders' review. Subsequent matters will be handled in accordance with the Beijing Stock Exchange rules. There is uncertainty during the transition period.